The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Issue 9 (21st September 2019)

• Record Type: Journal Article
• Authors: Kavanaugh, Arthur; Gottlieb, Alice; Morita, Akimichi; Merola, Joseph F; Lin, Chen-Yen; Birt, Julie; Shuler, Catherine L; Hufford, Matthew M; Thaçi, Diamant
• Is Part Of: Annals of the rheumatic diseases. Volume 78:Issue 9(2019)
• Page Start: 1215
• Publication Date: 2019-09-21
• Subjects: psoriatic arthritis -- psoriasis -- treatment -- health-related quality of life; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-215003
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: Determine the contribution of joint and skin improvements to health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Methods: SPIRIT-P1 and SPIRIT-P2 are phase 3 trials investigating ixekizumab, an interleukin-17A antagonist, in the treatment of patients with active PsA. Patients were randomised to ixekizumab or placebo. Outcomes included the Disease Activity Index for Psoriatic Arthritis (DAPSA), the Psoriasis Area and Severity Index (PASI), the European Quality of Life-Five Dimensions (EQ-5D) Visual Analogue Score (VAS), the 36-Item Short-Form Health Survey (SF-36) and the Work Productivity and Activity Impairment (WPAI) Questionnaire. The contribution of joint and skin improvements to HRQoL was modelled using a smoothing spline method and depicted with response surface graphics. Results: In this integrated analysis, 402 patients with PsA had baseline psoriasis of ≥3% of body surface area. We applied response surface modelling to this patient data set to investigate the relationship between DAPSA, PASI and HRQoL improvements at week 24. The greatest improvement in EQ-5D VAS was associated with the largest per cent improvements in both DAPSA and PASI together, rather than DAPSA or PASI alone. Similar observations were made in domains of SF-36 and WPAI. Conclusion: Optimal improvements in patients' HRQoL were dependent on successful treatment of both joint and skin symptoms.